Out to pi­o­neer gene edit­ing in Chi­na, Edi­Gene bags $67M to be­gin clin­i­cal test­ing for β-tha­lassemia ther­a­py, uni­ver­sal CAR-T

A gene edit­ing play­er hail­ing from Bei­jing has clinched $67 mil­lion to steer two of its lead can­di­dates in­to the clin­ic — and to prove it­self as a CRISPR pi­o­neer in Chi­na.

Dong Wei

Edi­Gene gath­ered the Se­ries B from a slate of top-tier Chi­nese in­vestors, in­clud­ing 3H Health In­vest­ment (who led the round), Se­quoia Cap­i­tal Chi­na, Al­win Cap­i­tal and Kun­lun Cap­i­tal. Pre­vi­ous back­ers, in­clud­ing IDG Cap­i­tal, Lil­ly Asia Ven­ture, Hua­gai Cap­i­tal and Green Pine Cap­i­tal Part­ners, al­so par­tic­i­pat­ed.

With the new cash, the biotech has of­fi­cial­ly crossed the $100 mil­lion mark in fundrais­ing over the past two years, ac­cord­ing to CEO Dong Wei.

“The round en­ables us to fur­ther scale up and trans­form our pipeline in­to clin­i­cal-stage, which is al­so a big step for­ward in build­ing a glob­al­ly com­pet­i­tive gene edit­ing com­pa­ny,” Wei said in a state­ment.

CRISPR may have had a bad rep in Chi­na in the af­ter­math of a scan­dalous hu­man ex­per­i­ment in which Jiankui He — who’s since been cast as a rogue sci­en­tist and sen­tenced to three years in jail — cre­at­ed the world’s first known gene edit­ing ba­bies by tin­ker­ing with a gene of an em­bryo in an at­tempt to con­fer pro­tec­tion against HIV. But Edi­Gene, which was launched in 2015 and has set up a BD of­fice in Cam­bridge, MA in ad­di­tion to head­quar­ters in Bei­jing and a GMP & ap­pli­ca­tion cen­ter in Guangzhou, clear­ly en­joys a dif­fer­ent po­si­tion.

“Edi­Gene is lead­ing the wave in Chi­na, as they have es­tab­lished out­stand­ing re­search and de­vel­op­ment ca­pa­bil­i­ties, and more im­por­tant­ly, they have de­vel­oped an im­pres­sive port­fo­lio of pro­pri­etary gene edit­ing tools and prod­uct can­di­dates,” said Minchuan Wang, a part­ner of 3H Health In­vest­ment.

Wen­sheng Wei

An ear­ly San Fran­cis­co trans­plant, Wei be­gan his biotech ca­reer at Ch­i­ron, took a de­tour in trad­ing and con­sult­ing, then worked his way through a slew of posts at Bio­Marin, Elan and J&J. His last role in the US — be­fore de­cid­ing in 2018 to move back and spend more time with fam­i­ly in Chi­na — was Shire’s glob­al de­vel­op­ment team leader for im­munol­o­gy.

It was nat­ur­al to then join Wen­sheng Wei, a co-founder of Edi­Gene and Dong Wei’s close friend from Peking Uni­ver­si­ty who end­ed up be­ing a PhD bud­dy at Michi­gan State Uni­ver­si­ty. By that time, Wen­sheng Wei was a pro­fes­sor at Peking Uni­ver­si­ty’s School of Life Sci­ences and had tasked Dong Wei with find­ing a CEO for Edi­Gene af­ter try­ing, in vain, to re­cruit him to the job.

The com­pa­ny boasts of four dif­fer­ent plat­forms re­volv­ing around CRISPR gene edit­ing tech: ex vi­vo edit­ing for hematopoi­et­ic stem cells, ex vi­vo edit­ing to cre­ate CAR-T cells, in vi­vo RNA-based edit­ing, as well as high-through­out genome edit­ing screen­ing for drug dis­cov­ery. Right now, the key pri­or­i­ties are ET-01 for se­vere β-tha­lassemia and U CAR-T ET-02 for can­cer.

Both are in­di­ca­tions where US biotechs have done ground­break­ing work, Dong Wei ac­knowl­edged in an in­ter­view with Pharm­Cube this March. Zyn­te­glo, blue­bird bio’s ex vi­vo ther­a­py for β-tha­lassemia, has al­ready been ap­proved in the EU.

But when he asked a friend — a blue­bird ex­ec — about whether that leaves any room for Edi­Gene on the mar­ket, the an­swer he got was blunt: Even though the Chi­nese pa­tient pop­u­la­tion is large, the coun­try’s pric­ing sys­tem and the re­quired in­vest­ment for man­u­fac­tur­ing doesn’t jus­ti­fy putting mon­ey be­hind it.

“When the com­pa­ny with the best tech­nol­o­gy in the world be­lieves there is no in­vest­ment val­ue in do­ing this in Chi­na, what should we do?” Wei said. “Are we just not go­ing to do it ei­ther?”

Ul­ti­mate­ly, he added, it all comes down to the ecosys­tem. In terms of the ac­tu­al gene edit­ing tech­nol­o­gy, he reck­ons that Chi­na is on par with in­ter­na­tion­al stan­dards — thanks to a serendip­i­tous over­lap in the tim­ing for de­vel­op­ment of gene edit­ing and the Chi­nese gov­ern­ment’s em­pha­sis on the biotech in­dus­try.

But the US is still way out front in terms of trans­la­tion, he not­ed:

For ex­am­ple, when a pro­fes­sor pub­lish­es a pa­per, you’d soon see re­searchers across Boston and San Fran­cis­co Bay Area fol­low­ing up on the tech­nol­o­gy. This is the aug­men­ta­tion ef­fect; or for ex­am­ple, 90% of VC in­vest­ment re­lat­ed to gene edit­ing is in Boston and 10% is in San Fran­cis­co — this is the clus­ter­ing ef­fect; and then if you look at the whole biotech field, San Fran­cis­co and Boston are es­sen­tial­ly equal, and to­geth­er they take up 80% of all Amer­i­can ven­ture in­vest­ing. All these are ecosys­tem ef­fects.

Mean­while in the US, say Wen­sheng pub­lished a new pa­per on gene edit­ing. Six months lat­er you’d sel­dom see oth­er labs ap­ply­ing this new tech to cre­ate new­er in­no­va­tion. This is like we con­quered a city, but didn’t have time to build the city in­to a bet­ter place.

At 5 years old and 100-plus em­ploy­ees, though, the con­struc­tion crew at Edi­Gene is ready to roll up their sleeves.

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

Since January 2020, the clinical trials ecosystem has quickly evolved to manage roadblocks impeding clinical trial integrity, and patient care and safety amid a global pandemic. Closed borders, reduced air traffic and delayed or canceled flights disrupted global distribution, revealing how flexible logistics and supply chains can secure the timely delivery of clinical drug products and therapies to sites and patients.

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.

Bob Nelsen (Photo by Michael Kovac/Getty Images)

Bob Nelsen rais­es $800M and re­cruits a star-stud­ded board to build the 'Fox­con­n' of biotech

Bob Nelsen spent his pandemic spring in his Seattle home, talking on the phone with Luciana Borio, the scientist who used to run pandemic preparedness on the National Security Council, and fuming with her about the dire state of American manufacturing.

Companies were rushing to develop vaccines and antibodies for the new virus, but even if they succeeded, there was no immediate supply chain or infrastructure to mass-produce them in a way that could make a dent in the outbreak.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.

Peter Thiel (Riccardo Savi/Sipa via AP Images)

Tech bil­lion­aire Pe­ter Thiel backs a lead­ing psy­che­del­ic drug de­vel­op­er

Right on the heels of investing in antibody drug developer AbCellera, Facebook billionaire Peter Thiel has jumped into a syndicate putting up $125 million for a company with a portfolio of psychedelic drugs in the clinic for mental health.

The C round — which includes a $32 million conversion of notes to equity — will fuel the development programs at ATAI Life Sciences, a Berlin-based biotech that has assembled a portfolio of companies with psychedelic and non-psychedilc approaches to depression, anxiety and addiction.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.

Vipin Suri, Catamaran Bio CSO

Cata­ma­ran Bio sails in­to the CAR-NK wa­ters with a $42M launch round

Catamaran Bio’s founding members decided to jump into the CAR-NK game last December over drinks at a trendy bar in Boston.

They were sitting around a table, discussing an MD Anderson study which provided some of the first clinical proof that natural killer (NK) cells can be reengineered to attack tumors, much like CAR-T therapies. It was a “long and lively” discussion, COO Mark Boshar recalls. And by the time it was over, they had a starting point to launch a company.

Am­gen sev­ers 14-year Cy­to­ki­net­ics part­ner­ship, bail­ing on ome­cam­tiv af­ter mixed PhI­II re­sults

Amgen is shrugging off a 14-year development alliance and the tens of millions of dollars spent to develop a new heart drug at Cytokinetics after a Phase III trial turned up weak data — leaving Cytokinetics to soldier on alone.

Omecamtiv mecarbil technically worked, meeting the primary composite endpoint in the Phase III GALACTIC-HF study. But it missed a key secondary endpoint, which analysts had been following as a key marker for success — reduction of cardiovascular (CV) death. While Cytokinetics celebrated the results, its stock tanked 43% upon the news, and analysts warned of an uncertain path ahead. Now, Amgen wants out.

News brief­ing: Ab­b­Vie part­ner Teneo­bio ex­pands tech li­cense with CAR-T play­er Po­sei­da; Ar­genx buys PRV from Bay­er for $98M

Teneobio may be best known for its pact with AbbVie and Gilead, but before its big break the bispecific player had licensed its antibodies for a different use: as binders in CAR-T therapies being developed by Poseida.

Now, the biotechs are expanding their partnership, with Poseida exercising four options to deploy Teneobio’s heavy chain only domain antibodies commercially.

The commercial licensing fees remained under wraps, but Teneobio is eligible for $250 million in milestones for these CAR-Ts against undisclosed targets.

Frank Zhang (AP Images)

Plot thick­ens around Leg­end Biotech, Gen­Script with founder Frank Zhang's ar­rest

Two months after Legend Biotech made the startling disclosure that founder and then-CEO Frank Zhang was placed under “residential surveillance,” its parent company revealed that he’s been formally arrested.

Zhang — who, since founding GenScript 18 years ago, has taken the CRO public and groomed Legend Biotech in-house until the J&J-partnered CAR-T player was mature enough for its own Nasdaq listing — is severing his final ties with both. He is resigning as board chair/non-executive director of GenScript and director of Legend.